Denteric’s GPV381 enters Phase 2, but can a therapeutic vaccine really change periodontitis care?
Denteric’s GPV381 has entered Phase 2 in periodontitis. Read why the gingipain-targeting vaccine could test a new treatment model.
Pharma & Biotech
Pharma & Biotech
Lupin Limited moves closer to the Wakix market as pitolisant tentative approval sharpens future optionality
Lupin Limited has won tentative FDA approval for pitolisant tablets. Read why timing, exclusivity, and Wakix market dynamics matter next.
Pharma & Biotech
Why GC Biopharma’s BARYCELA approval in Guatemala matters beyond one Latin American market
GC Biopharma won Guatemala approval for BARYCELA. Read what this means for Latin America, vaccine supply strategy, and varicella market competition.
Pharma & Biotech
Why Norgine’s PEDMARQSI approval in Switzerland could reshape cisplatin ototoxicity management
Swissmedic approved PEDMARQSI for cisplatin-related hearing loss in children. Read why this could reshape paediatric oncology supportive care.
Pharma & Biotech
Can Ono Pharmaceutical bring clearer treatment sequencing to advanced GIST in Japan?
Ono Pharmaceutical has filed ripretinib in Japan for advanced GIST. Read why the move could reshape late-line treatment access and sequencing.
Pharma & Biotech
How Tempus AI and Daiichi Sankyo are using real-world data to reshape antibody-drug conjugate development
Tempus AI and Daiichi Sankyo are using multimodal AI to refine ADC trial strategy and biomarker discovery. Read what this could change next.
Pharma & Biotech
Seaport Therapeutics’ Glyph platform faces its real test as GlyphAllo advances in depression
Seaport Therapeutics’ GlyphAllo data sharpen the case for oral neuroactive steroids in depression. Read what this could change next.
Pharma & Biotech
Can Corcept’s Lifyorli become a real new standard in platinum-resistant ovarian cancer after FDA approval?
Corcept’s Lifyorli won FDA approval in platinum-resistant ovarian cancer. Read what the survival data could change for clinicians, rivals, and regulators.
Pharma & Biotech
Can Merck’s $6.7bn Terns takeover turn TERN-701 into a post-Keytruda oncology pillar?
Merck is buying Terns for TERN-701. Read why this CML deal could reshape its hematology strategy and what risks still remain.
Pharma & Biotech
Nasus Pharma Ltd. expands intranasal platform as NS002 moves closer to regulatory pathway
Nasus Pharma Ltd. advances NS002 toward pivotal trials with faster epinephrine delivery. Discover what this means for anaphylaxis care.